GL1X · GenesisL1 explorer

Research workbench

Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor

Analyse Human CK2 catalytic domain in complex with a benzopyridoindole derivative… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3OWL
Type
protein
Length
330 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
CSNK2A1 protein
UniProt
Q5U5J2
Ligands
19E, SO4
Pockets
3 · best druggability 0.71

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACSNK2A1 proteinprotein33040% helix, 15% strandQ5U5J2

Ligands and binding sites

  • 19E · 11-chloro-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-3-ol · ligand · chains A
  • SO4 · Sulfate ion · ion · 3 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14020.710.824419E
2500.590.9219empty
3530.410.8213empty

Compared structures

  • 3OWL · Human CK2 catalytic domain in complex with a benzopyridoindole derivative inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.